<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309998</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000465498</org_study_id>
    <secondary_id>URCC-U1505</secondary_id>
    <secondary_id>GENENTECH-AVF3328S</secondary_id>
    <nct_id>NCT00309998</nct_id>
  </id_info>
  <brief_title>Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Vinorelbine Plus Bevacizumab as First Line Therapy in Patients ≥ 70 Years of Age With Stage IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some&#xD;
      block the ability of tumor cells to grow and spread. Others find tumor cells and help kill&#xD;
      them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor&#xD;
      cells by blocking blood flow to the tumor. Giving vinorelbine together with bevacizumab may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving vinorelbine together with&#xD;
      bevacizumab works in treating older patients with stage III or stage IV non-small cell lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Estimate the median time to disease progression in older patients with non-squamous&#xD;
           stage IIIB or stage IV non-small cell lung cancer (NSCLC) treated with vinorelbine&#xD;
           ditartate and bevacizumab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Estimate the response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Estimate the median survival in patients treated with this regimen.&#xD;
&#xD;
        -  Evaluate the safety of the combination of vinorelbine ditartate and bevacizumab in older&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive vinorelbine ditartate IV over 6 to 10 minutes on days 1 and 8 and&#xD;
      bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of&#xD;
      unacceptable toxicity or disease progression.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median time to disease progression by imaging study every 6 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate by imaging study every 6 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by toxicity (e.g thromboembolism, bleeding, or bowel perforation) every three weeks or as required</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-squamous, non-small cell lung cancer&#xD;
             (NSCLC)&#xD;
&#xD;
               -  Stage IIIB (any T, N3, M0 OR T4, any N, M0, OR pleural effusion) OR stage IV (any&#xD;
                  T, any N, M1) disease&#xD;
&#xD;
               -  Mixed tumors will be categorized by the predominant cell type unless small cell&#xD;
                  elements are present, in which case the patient is ineligible&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No lung carcinoma of squamous cell histology or any histology in close proximity to a&#xD;
             major vessel or cavitation&#xD;
&#xD;
          -  No known brain metastases, even if treated&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No other malignancies within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Transaminases ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Urine protein:creatinine ratio &lt; 1&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
          -  No prior ileus or neuropathy compromising use of vinorelbine ditartate&#xD;
&#xD;
          -  Patients with a history of hypertension must be well controlled (blood pressure &lt;&#xD;
             150/100 mm Hg) on a stable regimen of antihypertensive therapy&#xD;
&#xD;
          -  None of the following conditions:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  New York Heart Association grade II-IV congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Stroke within the past 6 months&#xD;
&#xD;
               -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
               -  Clinically significant peripheral vascular disease&#xD;
&#xD;
               -  Serious, nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
               -  History of hemoptysis (bright red blood ≥ ½ teaspoon)&#xD;
&#xD;
          -  No significant traumatic injury within the past 4 weeks&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             the past 6 months&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy for NSCLC&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent participation in another experimental&#xD;
             drug study&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy, hormonal therapy, or radiotherapy and&#xD;
             recovered&#xD;
&#xD;
          -  More than 28 days since prior major surgical procedure or open biopsy&#xD;
&#xD;
               -  No anticipation of need for major surgery during course of trial&#xD;
&#xD;
          -  More than 7 days since prior minor surgical procedures (e.g., fine-needle aspiration&#xD;
             or core biopsy)&#xD;
&#xD;
          -  No concurrent full-dose anticoagulation therapy for thromboembolic disease, aspirin (&gt;&#xD;
             325 mg/day), or nonsteroidal anti-inflammatory drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak M. Sahasrabudhe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>James P. Wilmot Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <name_title>Deepak M. Sahasrabudhe</name_title>
    <organization>James P. Wilmot Cancer Center at University of Rochester Medical Center</organization>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

